Podcasts about wegovy

Kara and Scott discuss the advancement of a bill to ban stock trading by lawmakers, President Trump's Joe Rogan problem, and Ghislaine Maxwell agreeing to testify for immunity. Then, President Trump says he will not extend the latest August 1st tariff deadline, and Microsoft and Meta's mega earnings. Plus, Novo Nordisk shares are plummeting after weak growth for Ozempic and Wegovy. Watch this episode on the ⁠⁠Pivot YouTube channel⁠⁠.  Follow us on Instagram and Threads at ⁠⁠@pivotpodcastofficial⁠⁠.  Follow us on Bluesky at ⁠⁠@pivotpod.bsky.social⁠⁠.  Follow us on TikTok at ⁠⁠@pivotpodcast⁠⁠.  Send us your questions by calling us at 855-51-PIVOT, or at ⁠⁠nymag.com/pivot⁠⁠.⁠⁠ Learn more about your ad choices. Visit podcastchoices.com/adchoices

Episode 637: Neal and Toby chat about Boeing's strongest quarter yet as it seems to have successfully turned the tides of its performance. Then, Novo Nordisk, the maker of Ozempic and Wegovy, are losing the lead to other competitors and copycat drugs. Also, the AI surge is also causing a surge in electricity bills for the locals who live around these massive data centers. Plus, Uggs are becoming popular footwear for men as celebrities help boost sales.  Build your Range Rover Sport at RangeRover.com/US/Sport  Subscribe to Morning Brew Daily for more of the news you need to start your day. Share the show with a friend, and leave us a review on your favorite podcast app. Listen to Morning Brew Daily Here:⁠ ⁠⁠https://www.swap.fm/l/mbd-note⁠⁠⁠  Watch Morning Brew Daily Here:⁠ ⁠⁠https://www.youtube.com/@MorningBrewDailyShow⁠ 00:00 - Tsunami warning 2:40 - Boeing bounces back 8:20 - Novo Nordisk loses its edge 11:50 - AI is making electric bills higher 17:50 - Uggs, they're for men too! 21:00 - Sprint Finish!

David Faber and Jim Cramer kicked off a big show with Starbucks CEO Brian Niccol in a "First on CNBC" interview on the company's quarterly results and turnaround plan. Palo Alto Networks CEO Nikesh Arora and CyberArk Software Founder and Executive Chairman Udi Mokady appeared on the program to discuss their companies' $25 billion merger deal.National Economic Council Director Kevin Hassett joined the show with White House reaction to stronger-than-expected Q2 GDP, as well as views on tariffs and the Fed on rate decision day for the central bank. Also in focus: Earnings parade winners and losers, more woes for Wegovy maker Novo Nordisk. Squawk on the Street Disclaimer

Send us a textDr. Meghan Garcia-Webb has been helping CEOs, attorneys, physicians, and consultants look and feel better for years, and she is attuned to the concerns of high achieving individuals, as well as the specific mindset traps that befall even the most organized personality.She is board-certified in Internal Medicine, Lifestyle Medicine, and Obesity Medicine, bringing her patients the latest evidence-based therapies. She is also certified as a life coach through The Life Coach School, the premier choice for physician coaches. Through this unique combination of skills, she has pioneered an innovative hybrid model of customized care, creating lasting results for patients with ease.Dr. Garcia-Webb earned her B.S. at Tufts University, and her M.D. from the University of Vermont Medical School. She completed her residency in internal medicine at the University of Massachusetts. In addition to her clinical work, she produces a weekly YouTube series, Weight Medicine with Dr. Meghan.Dr. Garcia-Webb has been featured in publications such as Time, GQ, Food & Wine, The NY Post, Men's Health, Newsweek, Prevention, and Parade magazine.Find Dr. Meghan Garcia-Webb at-YT- @Weight Medicine with Dr. Meghan MDhttps://weightmedicinemd.com/Find Boundless Body at- myboundlessbody.com Book a session with us here!

Thursday 31 July 2025 A drop in inflation opens the way for interest rate cuts. And more, including: Australia edges closer to calling for a separate state of Palestine. The federal government adds YouTube to the list of social media sites banned for young teenagers. An Australia-EU free trade deal looks to be faltering The share price of weight loss drug group Novo Nordisk tumbles 30pc on disappointing sales of Ozempic and Wegovy. Join our free daily newsletter here. And don’t miss the latest episode of How Do They Afford That? - this week, cash or cashless: what’s better for the budget? Get the episode from APPLE, SPOTIFY, or anywhere you listen to podcasts.Find out more: https://fearandgreed.com.auSee omnystudio.com/listener for privacy information.

Plus: JPMorgan Chase nears a deal to take over Apple's credit-card program. And U.S. consumers' economic mood improved this month, but they remained concerned about tariffs and the labor market. Pierre Bienaimé hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Carl Quintanilla, Jim Cramer and David Faber led off the show with a mega-deal to create a transcontinental railroad giant: Union Pacific to acquire Norfolk Southern for $320 a share or $72 billion in cash and stock. Boeing CEO Kelly Ortberg joined the program along with Phil LeBeau after the company slashed losses and posted a Q2 beat. Novo Nordisk shares plunge after the Wegovy maker cuts guidance and appoints a new CEO.  Procter & Gamble reports earnings and names its future CEO. UnitedHealth slides on weak 2025 guidance. Also in focus: A slew of earnings winners and losers, the deadly shooting inside an office tower on Park Avenue in New York City. Squawk on the Street Disclaimer

Thinking about trying Ozempic, Wegovy, or Monjaro? You're not alone. In this episode, Brooke unpacks the pros, cons, and common misconceptions around semaglutide medications for postpartum moms. If you're navigating weight loss, breastfeeding, or just trying to feel like yourself again—this one's a must-listen. What to Listen For: Why semaglutides like Ozempic are not safe during pregnancy or breastfeeding The hormonal impact of semaglutides and why that matters for moms What happens when you stop taking semaglutides without making lifestyle changes Real talk on the side effects—nausea, vomiting, diarrhea, and more Why some moms regret weaning early just to lose weight What blood sugar imbalance means and how to fix it without meds When Brooke might recommend a semaglutide—and when she wouldn't The link between protein, blood sugar, and milk supply How semaglutides may decrease milk supply by affecting prolactin and oxytocin Why slow, sustainable weight loss preserves muscle (and feels better) Semaglutides can seem like a quick fix—but for most postpartum or breastfeeding moms, they're more risk than reward. Brooke encourages moms to first nourish their bodies with real food, movement, and sustainable changes. Medications may have a time and place, but not at the expense of your hormones, energy, or milk supply. --------------------------------------------------------------------------------------------- Breakfast is one of the most important meals of the day, and getting it right can make a huge difference in your energy, mood, and overall health postpartum. If you've been making these common mistakes, don't stress—small changes can have a big impact! Grab my Postpartum Breakfast Guide for easy, balanced meals that will leave you feeling nourished and satisfied. Click the link in the show notes to get yours today! Click Here to Join the Free Workshop: How to Feel Like Yourself Again Postpartum & Reach Your Healthiest Weight without Sacrificing Your Favorite Foods or Milk Supply

Tuesday morning showed a tale of two companies. Novo Nordisk (NVO) sold off more than 20% after making heavy reductions to sales guidance for its Ozempic and Wegovy weight loss drugs. Meanwhile, SoFi Technologies (SOFI) climbed with a strong showing in its fintech earnings. Jenny Horne goes over the biggest morning movers before the opening bell.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Stocks closed down as tariff talks between the U.S. and China continued for a second day in Sweden. Most earnings didn't offer hope for positive trading action, seen in Novo Nordisk's (NVO) 22% decline after curbing sales expectations for Wegovy and Ozempic. Spotify (SPOT) also saw a staggering sell-off after posting a surprise miss. However, SoFi Technologies (SOFI) offered a bright spot with its rally. Marley Kayden talks about the biggest earnings movers of the session.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Beleggers van farmaceut Novo Nordisk zijn afvallig. Het aandeel wordt gedumpt, want de directie komt met misselijkmakend nieuws. Er is voor de tweede keer dit jaar een winstwaarschuwing en als toetje komt daar nog een omzetwaarschuwing bovenop.De verkoop van de afvalprikken van Novo Nordisk vallen tegen. Concurrent Eli Lilly doet het beter. Alleen profiteert het aandeel van de concurrent niet van de neergang van Novo Nordisk. Sterker nog: die gaat ook hard onderuit. Beleggers denken namelijk dat de hele sector overdreven is.Daar hebben we het deze aflevering over. Is de markt voor afvalmedicatie niet gewoon een hype?Hoor je ook over heel veel ander nieuws, want het was een drukke beursdag. Philips bijvoorbeeld, dat hield een zegetocht op de Amsterdamse beurs. Eens géén winstwaarschuwing voor Philips, maar juist een opwaardering voor de winst. Een bedankje daarvoor kan naar het Witte Huis.Waar dan geen muziek in zit, is Spotify. De streamer stelt teleur en dat is heel lang geleden. Er komen meer abonnees bij, maar Spotify maakt onverwachts verlies.Verder in deze aflevering: De Britten hebben een betere deal de EU. Keir Starmer blijkt goede dealmaker Alfen vindt een nieuwe ceo Jerome Powell kan opgelucht ademhalen: Fed-vergaderingen hoeven niet openbaar ECB-werknemers happen juist naar adem. Lagarde zou werksfeer verpesten Kwartaalcijfers van Basic-Fit blijken niet echt fit See omnystudio.com/listener for privacy information.

A quick 101 | the side effects and those news headlines | the longevity link | the wider concerns | slimming pills | Ozempic and fertility | muscle loss | the positives

Beleggers van farmaceut Novo Nordisk zijn afvallig. Het aandeel wordt gedumpt, want de directie komt met misselijkmakend nieuws. Er is voor de tweede keer dit jaar een winstwaarschuwing en als toetje komt daar nog een omzetwaarschuwing bovenop.De verkoop van de afvalprikken van Novo Nordisk vallen tegen. Concurrent Eli Lilly doet het beter. Alleen profiteert het aandeel van de concurrent niet van de neergang van Novo Nordisk. Sterker nog: die gaat ook hard onderuit. Beleggers denken namelijk dat de hele sector overdreven is.Daar hebben we het deze aflevering over. Is de markt voor afvalmedicatie niet gewoon een hype?Hoor je ook over heel veel ander nieuws, want het was een drukke beursdag. Philips bijvoorbeeld, dat hield een zegetocht op de Amsterdamse beurs. Eens géén winstwaarschuwing voor Philips, maar juist een opwaardering voor de winst. Een bedankje daarvoor kan naar het Witte Huis.Waar dan geen muziek in zit, is Spotify. De streamer stelt teleur en dat is heel lang geleden. Er komen meer abonnees bij, maar Spotify maakt onverwachts verlies.Verder in deze aflevering: De Britten hebben een betere deal de EU. Keir Starmer blijkt goede dealmaker Alfen vindt een nieuwe ceo Jerome Powell kan opgelucht ademhalen: Fed-vergaderingen hoeven niet openbaar ECB-werknemers happen juist naar adem. Lagarde zou werksfeer verpesten Kwartaalcijfers van Basic-Fit blijken niet echt fit See omnystudio.com/listener for privacy information.

GLP-1 medications like Ozempic and Wegovy are changing how the medical system approaches obesity and metabolic disease. But are they a replacement for dietary intervention? Or are dietary interventions a replacement for these medications? Could they be used together for even better outcomes?In this conversation, Dr. David Ludwig (Harvard, Boston Children's Hospital) and journalist Gary Taubes explore the science behind GLP-1s, their impact on insulin, weight loss, and chronic disease, and where dietary strategies like low carb or ketogenic therapy fit in.They break down:The overlap between GLP-1 drugs and low carb dietsWhy long-term use of these drugs may come with hidden costsHow shared mechanisms open the door to combination therapyWhat current studies are missing and the urgent need for better trialsWhy metabolic health (not just weight loss) should be the focusThis conversation challenges the idea that the answer is either medication or nutrition therapy. The reality is that every individual is different, and for many, the most effective path to healing may involve a thoughtful combination of both. Rather than choosing one over the other, we should focus on tailoring care to the unique needs of each individual with the goal of getting the best outcomes.Expert Featured:Dr. David LudwigX: https://x.com/davidludwigmdGary Taubeshttps://x.com/garytaubeshttps://uncertaintyprinciples.substack.com/Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry.Learn more about metabolic psychiatry and find helpful resources at https://metabolicmind.org/About us:Metabolic Mind is a non-profit initiative of Baszucki Group working to transform the study and treatment of mental disorders by exploring the connection between metabolism and brain health. We leverage the science of metabolic psychiatry and personal stories to offer education, community, and hope to people struggling with mental health challenges and those who care for them.Our channel is for informational purposes only. We are not providing individual or group medical or healthcare advice nor establishing a provider-patient relationship. Many of the interventions we discuss can have dramatic or potentially dangerous effects if done without proper supervision. Consult your healthcare provider before changing your lifestyle or medications.

More people than ever are turning to medicine for weight loss, but how do you know if it's right for you? In this episode, I dive into the hot topic of weight loss medications and tackle the myths, science, and facts behind them. As a board-certified obesity medicine specialist, I explain who qualifies for medications like Wegovy, Zepbound, and others, how they work, and why obesity is a chronic condition, not a personal failure. I will walk you through the medical, hormonal, and genetic factors that influence treatment, outline FDA guidelines, and share how I assess whether a patient is a good candidate. I also discuss common misconceptions, long-term use, and tips for having an informed conversation with your doctor. Because remember, It's not about shortcuts, it's about finding the right tools to improve your health and quality of life. Tune in to learn the truth about weight loss medications, debunk common myths, and find out if they're the right fit for your health journey.   Episode Highlights: Who qualifies for weight loss medications FDA-approved options Common myths debunked about weight loss drugs How GLP-1 medications work and their long-term role in obesity treatment Key factors doctors assess before prescribing Contraindications and who should not take these medications How to talk to your doctor about medical weight loss options Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Christian Bonde har i årevis været en stemme i dansk radio og podcast, senest med podcastene “Christian Bondes Spilpodcast” og “Fantino og Bonde”. I dagens afsnit taler vi om mediebranchen, samarbejdet med Maria Fantino og de overvejelser, der følger med, når man skal finde sin plads i det hele. Vi snakker også om Wegovy, gaming, og hvordan det hele spiller sammen med hverdagen – og livet – på Amager.Vil du høre resten? Så find hele episoden eksklusivt på Podimo:http://podimo.dk/christian

In this episode of The Wisdom of Wellness, Dr. Kayla Lucas sits down with Dr. Vivek Lal—a double board-certified MD and founder of ResBiotic—to unpack the powerful (and often overlooked) role the gut plays in our mood, metabolism, and modern-day disease.

Professor Clare Collins delves into the world of nutrition and obesity medications with Sally Badorrek, Accredited Practising Dietitian from the University of Sydney. With 25 years of clinical experience in nutrition management of chronic conditions like obesity and diabetes, Sally shares insights on the latest medications, their side effects, and the importance of a holistic approach to weight management. We discuss the science behind new obesity medications like Semaglutide and Tirzepatide, how they work, common side effects and strategies to manage them, plus the critical role dietitians play in supporting patients on these medications. Together they unpack some myths and misconceptions around obesity treatments and discuss why a team-based approach is key to long-term health gain.Listen now to gain a deeper understanding of how these medications can aid in weight management and improve overall health. Whether you're a health professional, someone navigating weight management, or simply curious about the future of obesity care, this episode offers practical insights and compassionate perspectives.No Money No Time: Food and Mood Diary for tracking dietary habitsNo Money No Time: To access the FREE Healthy Eating Quiz: Click on the top right hand 'green button' called 'How healthy is my diet'No Money No Time closed Facebook group (be sure to take the Healthy Eating Quiz first)Find an Accredited Practising Dietitian hereDo you want a more Personalised Food, Nutrient Assessment Report? Our Australian Eating Survey includes an assessment of your nutrient (vitamin and mineral) intake. Use code 'DietCheck' at the checkout for 50% off! Purchase hereAre you in a position to make donation to support our No Money No Time website? Donate here#ObesityTreatment #DietitianAdvice #WeightManagement #Ozempic #Tirzepatide #Wegovy #ObesityMedication #Sideeffects Hosted on Acast. See acast.com/privacy for more information.

This week on Mum Club 101, we're covering everything from toddler chaos to one of the most debated parenting topics of the year.Catch-Up:Vicky shares her third trimester update, including her experience with the gestational diabetes test and pregnancy vaccines. Meanwhile, Katy reflects on the logistics (and sheer stamina required) of managing two toddlers at swimming lessons.Critique of the Week:Should children as young as 11 be prescribed weight-loss injections?We're diving into a controversial and emotionally charged topic this week, sparked by a viral This Morning interview with an 11-year-old girl named Sophia and her mum. Sophia shared her painful experience of bullying, body image struggles, and why she asked to go on weekly GLP-1 injections like semaglutide (Wegovy) or liraglutide (Saxenda).We explore the clinical context, ethical concerns, and emotional layers behind the use of weight-loss medication in children—particularly when it's prescribed off-label.Is this a compassionate medical response to a growing health crisis, or a troubling message about bodies and self-worth?Please note: this segment contains sensitive discussion around childhood weight, bullying, and body image. If this topic feels heavy for you today, feel free to skip ahead or listen when you're ready.If you or your child is struggling with food, body confidence, or emotional wellbeing, you are not alone. Support is available:BEAT Eating Disorders | Helpline: 0808 801 0677YoungMinds – Mental health support for young people and parentsLink to Interview on This Morning Nonsense Time:We try to guess the meaning of words from other languages that don't have a direct English translation. Spoiler: we're mostly wrong.

I denne uges episode taler vi lidt mere om brugen af de her semaglutid produkter, som Wegovy hører under. Bliver det brugt som præstationsfremmende middel? Og er min producer, Jacob, kommet igang med Wegovy siden vi talte om det sidst? Rigtig god fornøjelse Har du et ønske om at arbejde sammen med mig i 2025 eller 2026? Så lad mig høre fra dig snarest muligt via én af nedenstående medier: mail@jschristensen.dk Eller send mig en DM via min instagram: @byjschristensen Du kan følge med på: Instagram & TikTok: @byjschristensen Facebook: Jacob Christensen - Coach & Personlig træner Og du kan skrive dig op til forløb via: www.jschristensen.dk mail@jschristensen.dk @byjschristensen på instagram

REDIFF - Benjamin Castaldi n'a pu s'empêcher de réagir à l'arrivée du "Wegovy", ce produit présenté comme une solution révolutionnaire contre l'obésité. Un traitement qui l'inquiète, car il pourrait bien menacer son emploi... Cet été, retrouvez tous les jours le meilleur de Laurent Gerra en podcast sur RTL.fr, l'application et toutes vos plateformes.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this week's Five Minute Friday, Dr. Kay dives into the hot topic of Ozempic Face — the facial volume loss and sagging that can occur with rapid weight loss from GLP-1 medications like Ozempic, Wegovy, and Mounjaro. She explains what causes these changes, how to recognize the signs, and when to take action. Learn how strategic filler placement, collagen-stimulating injectables like Radiesse, Sculptra, and Renuva, and preventative planning can help restore youthful structure and preserve your facial foundation. Whether you're just starting weight loss or already seeing changes, this episode is your guide to looking as vibrant as you feel.

Welcome back to Ozempic Weightloss Unlocked, where we dive deep into the latest science, news, and real-world impacts of Ozempic and similar medications. Today, we're unpacking the newest discoveries about these increasingly popular weight loss drugs, their benefits, their risks, and how they're changing lives and medical thinking in 2025.First, let's get current: The spotlight on Ozempic, Wegovy, and related medications has never been brighter. Texas Health reports that these drugs, originally developed to manage type two diabetes, are being prescribed off-label for weight loss. They are part of a class called GLP-1 receptor agonists, mimicking a natural hormone that reduces appetite and improves blood sugar levels.According to Buckhead Primary Care Clinic, a recent 2024 study found that people who used Ozempic for four straight years maintained an average ten percent weight loss. That is significant, showing lasting results for long-term users. Other studies, compiled by ScienceAlert and The Independent, indicate that the majority of weight lost during treatment tends to return after stopping the drug, with some regaining weight in as little as eight weeks and the average participant gaining back five and a half pounds within twenty weeks of stopping.The reasons for the regain are still being investigated. Researchers suggest the body's metabolism might adapt to weight loss in ways that make long-term maintenance challenging. Lifestyle factors like exercise, diet, and whether participants had diabetes were taken into account, but a trend of weight cycling was observed. This weight cycling—losing weight and then regaining it—has unknown long-term impacts on health, and more research is underway.Now, what about muscle and fitness? A recent analysis by UVA Health, discussed by ScienceNews and other outlets, found that while Ozempic and similar drugs are effective at shedding pounds, they do little to improve cardiorespiratory fitness, which is a critical measure of health and longevity. More concerning, patients can lose “fat-free mass” during treatment—up to fifty percent of what's lost could be muscle, not just fat. That's why experts like Dr. Liu from UVA recommend combining medication with regular exercise and adequate dietary protein, to preserve muscle and maximize well-being.On the innovation front, new delivery methods are in the pipeline. ScienceNews reports that researchers at Stanford have developed a hydrogel that, once injected with Ozempic or Mounjaro, could maintain steady drug levels for weeks, potentially reducing injections from fifty-two a year to just four. Although still in animal trials, this technology could make ongoing treatment much more user-friendly in the future.The cultural impact is also significant. As Business Insider outlines, about one in eight adults in the United States are now taking a GLP-1 medication. These drugs have helped alter the narrative around obesity, framing it as a medical condition instead of a personal failing. However, the increased popularity has led to rising cases of eating disorders tied to the medications, and some clinicians now warn about new risks for those with a history of restrictive eating or who don't need the medication medically.Another debate is brewing over guidelines for children and teens. Stat News uncovered that more than a third of those who developed pediatric obesity guidelines had financial ties to drug manufacturers, raising concerns about impartiality and the wisdom of prescribing these strong medications to young people.To wrap up, the current consensus is that Ozempic and similar drugs represent a major advancement in obesity treatment, especially for people with type two diabetes or severe obesity. However, experts stress that these medications work best when combined with lasting lifestyle changes such as healthy eating, regular exercise, and ongoing medical guidance. Weight loss medication is often not a quick fix but part of a much larger, longer-term health plan.Thank you for tuning in to Ozempic Weightloss Unlocked. For ongoing coverage and honest discussion about the future of weight loss medicine, be sure to subscribe. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Ozempic has dominated headlines once again this week as new research and high-profile celebrity discussions underscore its impact on the weight loss landscape in 2025. Ozempic, part of the class of medications known as glucagon-like peptide-1 receptor agonists or GLP-1 drugs, was initially approved for managing type 2 diabetes but rapidly gained popularity for its striking effects on weight loss. According to Science Alert, a comprehensive review of clinical studies released in the past week highlights that while people see significant and often rapid weight loss while on these medications, discontinuing them results in almost immediate weight regain. Researchers from Peking University documented how many participants began to regain pounds as early as eight weeks after stopping medications like Ozempic or Wegovy, with body weight rising steadily for up to twenty weeks post-treatment. This review found that individuals who lost more weight on the medication had a higher risk of regaining it, although why this happens is not yet well understood. According to The Independent, contributing factors may include changes in metabolism or appetite regulation, and real-world experiences confirm that the weight rebound can be swift and distressing for many. Another visible trend is the increasing use of Ozempic by individuals who may not meet the original criteria for treatment, such as those without type 2 diabetes or severe obesity. Business Insider reports that about one in eight adults in the United States is now taking a GLP-1 medication, either for diabetes or primarily for weight loss. This surge includes a growing number of people with eating disorders who hope the medication might quiet what some describe as "food noise," only to find that it can worsen existing issues or trigger new eating disorders. Clinical centers nationwide are reporting more cases of patients with disordered eating turning to these drugs, which presents a worrying challenge for professionals trying to balance medical necessity against psychological risk. In one prominent example shared by Business Insider, a woman named Rose, with a decades-long history of bulimia and restrictive eating, felt validated seeking Ozempic after developing diabetes. However, her care team expressed concern that the medication could compromise her recovery and even endanger her health due to further weight loss.The cultural conversation is magnified by celebrities speaking out about their journeys, with Oprah Winfrey continuing to play a central role in shaping public dialogue. Reports by People and KoiMoi this week revisit her evolution from criticizing weight loss medications as "the easy way out" to openly embracing Ozempic as part of her personal strategy. In a recent WeightWatchers special, Oprah reflected on how her previous public advocacy for extreme diet methods was misguided and even apologized for promoting unsafe diet culture on her talk show and magazine. She disclosed that she lost forty pounds with Ozempic, emphasizing that while medication helped her reduce constant thoughts about food, genuine progress included changes in diet, increased physical activity, and a fundamental shift in mindset. Winfrey now encourages a more holistic, less judgmental approach to weight management, an attitude echoed by other celebrities like Lizzo, Meghan Trainer, and Whoopi Goldberg, all of whom recently revealed their experiences with weight loss drugs or lifestyle interventions.A crucial message emerging this week is that while GLP-1 drugs like Ozempic can deliver rapid results, experts and researchers caution that sustainable long-term weight loss still requires dietary regulation, exercise, and ongoing medical oversight. AOL and The Independent both emphasize that ceasing Ozempic often results in patients regaining most or all of their lost weight, sometimes within just a few months. Furthermore, medical professionals warn that returning to the medication after a break requires careful management to minimize side effects. There are also significant concerns about individuals using the medication for cosmetic weight loss or as a quick fix when they may not meet clinical criteria, particularly among those with a history of disordered eating.For listeners navigating this evolving topic, Ozempic remains a complex tool—an effective intervention for some when managed professionally, but fraught with challenges around misuse, sustainability, and mental health. The cultural narrative is shifting from miracle cure to nuanced understanding, as research and personal stories bring both possibilities and pitfalls into clearer focus. Thank you for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Fat loss - when done right, it's boring! That's exactly what we're talking about this week - the boring basics from fat loss plateaus to pizza trade-offs, we break down the boring basics most people skip, and why that's exactly where you need to focus. We talk about macros, periodizing calorie deficits, emotional eating, volume vs. satisfaction, and the importance of performance-based goals.We also dive into a powerful (and disturbing) conversation about a viral interview where an 11-year-old was prescribed Wegovy - and why this signals a dangerous generational cycle of diet culture repeating itself yet again. Expect unfiltered takes, zero fluff, and practical mindset shifts you can use now - no fancy weight loss supplements or cortisol morning routines needed.Topics Covered:Why long, aimless calorie deficits backfireThe difference between volume eating and just “eating more”The mental side of food boredom and emotional hungerWhen macros help and when they become a distractionWhy your goal shouldn't just be fat lossWhy it's time to stop outsourcing your decisions to influencersShoutouts:Beth's 5K a Day for Sobriety (starting Aug 1)Amy crushing it with our Patreon workoutsFit Fat Strong July Book Club: The Mountain Is YouThank you Cured Nutrition for sponsoring our podcast!We LOVE Cured products and know you will, too! Whether it's popping a Serenity gummy to help you take the edge off after a long day, or taking a Flow gummy to help you crush your workout - Cured has something for you. ⁠⁠⁠⁠Enter our code 'CTC' to receive 20% off your purchase from Cured Nutrition!⁠⁠⁠Follow the pod: ⁠@cutthecrapwithbethandmatt⁠Follow your hosts:Beth: ⁠@bethferacofitness⁠Matt: ⁠@mattlaarfit⁠Join our Patreon for monthly workouts, challenges, recipes, and to become part of the Cut The Crap Community! Become a member today for exclusive content and to support our podcast: ⁠⁠⁠⁠⁠⁠⁠https://www.patreon.com/cutthecrappodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠Visit our website to learn more about us, contact us, inquire about collaborating with us and more: ⁠⁠⁠⁠⁠⁠⁠https://www.cutthecrappod.com/⁠⁠⁠Like this episode? Why not share it with a friend!Send us a DM on Instagram to let us know what you think of this one, and with episode ideas! If we use your comment or suggestion, we'll give you a shoutout on the podcast!

Angela examines the complexities of food noise and the impact of GLP-1 medications with Dr. Jack Mosley, author of "Food Noise." They explore why some individuals experience more food cravings than others, discussing the interplay of genetic and environmental factors, as well as the emotional components tied to eating. KEY TAKEAWAYS Food Noise and Cravings: Individuals experience varying levels of "food noise," or cravings, influenced by genetic predispositions and environmental factors Nutritional Deficiencies: Many people are overfed but undernourished, leading to cravings driven by nutrient insufficiencies GLP-1 Medications: GLP-1 medications, such as Ozempic and Wegovy, work by regulating blood sugar, slowing gastric emptying, and affecting brain pathways Importance of Lifestyle Changes: While GLP-1 medications can aid in weight loss, they should be accompanied by lifestyle changes, including a nutritious diet and regular exercise TIMESTAMPS AND KEY TOPICS [00:05:25] GLP-1 and appetite reduction. [00:09:14] Rapid weight loss and muscle loss. [00:20:06] Importance of muscle in aging. [00:36:09] Scurvy and modern nutrition. [00:41:54] Weight loss medications and recipes. VALUABLE RESOURCES Get a free snapshot of your health and personalised report at www.yourtotalhealthcheck.com Join The High Performance Health Community Sign Up to Angela's Weekly Fresh Starts Email to transform your health, energy, and longevity with just ONE small habit every week - angelafoster.me/freshstart Food Noise: How weight loss medications & smart nutrition can silence your cravings https://amzn.eu/d/82fCVHP  Intermittent Fasting, Intelligent Exercise & Simple Habits to Boost Longevity & Performance with Dr Michael Mosley  https://lnk.to/EP_202 ABOUT THE GUEST Jack studied medicine at Newcastle University and received a Distinction in his Masters of Research in diabetes with Professor Roy Taylor, whose remarkable work proved the transformative effect of weight loss and diet on type 2 diabetes, leading many hundreds of thousand putting their diabetes into remission ABOUT THE HOST Angela Foster is an award winning Nutritionist, Health & Performance Coach, Speaker and Host of the High Performance Health podcast. A former Corporate lawyer turned industry leader in biohacking and health optimisation for women, Angela has been featured in various media including Huff Post, Runners world, The Health Optimisation Summit, BrainTap, The Women's Biohacking Conference, Livestrong & Natural Health Magazine. Angela is the creator of BioSyncing®️ a blueprint for ambitious entrepreneurial women to biohack their health so they can 10X how they show up in their business and their family without burning out. Angela's BioSyncing®️ Blueprint is currently closed. Click here to get on the waitlist. CONTACT DETAILS Instagram Facebook LinkedIn Disclaimer: The High Performance Health Podcast is for general information purposes only and do not constitute the practice of professional or coaching advice and no client relationship is formed. The use of information on this podcast, or materials linked from this podcast is at the user's own risk. The content of this podcast is not intended to be a substitute for medical or other professional advice, diagnosis, or treatment. Users should seek the assistance of their medical doctor or other health care professional for before taking any steps to implement any of the items discussed in this podcast.

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are reshaping how we treat obesity — but there's so much confusion and stigma. That's why we sat down with leading obesity specialist Dr. Spencer Nadolsky for an honest, empowering conversation.We break down how GLP-1s actually work, why food noise is real, and what people aren't being told about compounded semaglutide, weight regain after bariatric surgery, and long-term success.If you've felt frustrated, misunderstood, or stuck — this episode is for you. Whether you're post-op, on medication, or considering your options, this episode brings science, support, and real talk together.

We're in an era where GLP-1 medications like Ozempic and Wegovy are everywhere. On TV, in social media feeds, at the doctor's office, and in everyday conversations. And while these medications may be helpful or even life-changing for some, they're also bringing up a lot of complicated feelings for many others, especially those who are choosing not to take them, or are trying to navigate their use in a weight-centric world. This episode holds space for those feelings. We're not here to judge anyone's decisions. Whether you're on a GLP-1, thinking about it, or actively avoiding it, this conversation is for you. Because no matter what, you're making decisions in a culture steeped in weight stigma, misinformation, and unrealistic expectations. In this episode: Why seeing GLP-1 use everywhere can be triggering—even if you support body neutrality The influence of diet culture, media, and peer pressure on health decisions Personal reflections on navigating this era in a larger body Questions to ask yourself before making health-related decisions How self-compassion and boundary-setting can protect your mental health Reframing weight loss narratives: why thin doesn't always mean healthy A reminder that you don't know anyone's full story Sign up for Tara's Newsletter: https://mailchi.mp/5290e3f13e08/email-signup The Ultimate Self Care Planner: https://elizabethharrisnutrition.ck.page/9e817ab37e   Elizabeth Harris, MS, RDN, LDN FB: Health and Healing with Intuitive Eating community https://www.facebook.com/groups/healthandhealingwithintuitiveeating Instagram: https://www.instagram.com/ElizabethHarrisNutrition Free download to break up with diet culture: https://elizabethharrisnutrition.com/invisible-diet   Tara De Leon, Master Personal Trainer Email: FitnessTrainer19@hotmail.com Instagram: https://www.instagram.com/tara_de_leon_fitness Join Tara's Newsletter: https://mailchi.mp/5290e3f13e08/email-signup Maria Winters, LCPC, NCC Instagram: https://www.instagram.com/coaching_therapist/ FB: https://www.facebook.com/MWcoachingtherapy Website: www.thecoachingtherapist.com Attend an Emotional Fitness Studio Class: https://thecoachingtherapist.com/emotional-fitness-studio/

Click here to text us!Hello friends! In this episode, I am delighted to have Dr. Sarah Stombaugh on the podcast. We explore the popular GLP-1 medications you may have heard about—Ozempic, Wegovy, Mounjaro—and talk about how they work, who they're designed for, and what makes them effective. We also unpack some of the concerns around these medications, including who should avoid them and what needs to be in place for long-term success.Dr. Stombaugh explains how these medications fit into a much bigger picture that includes nutrition, movement, sleep, and stress management. For women in perimenopause and menopause who are seeing changes in their weight and metabolism, this conversation offers clarity and reassurance. Whether you've struggled with weight your whole life or are seeing shifts for the first time, you'll find helpful information here.We also talk about Dr. Stombaugh's excellent online resource, The GLP Guide, created to support people using these medications outside of a comprehensive care program.Dr. Stombaugh's approach is science-based, compassionate, and refreshingly practical. I think you're going to love what she shares.Show Notes:Grab the Breakfast Guide Here!Connect with Sarah Stombaugh, MD on:Dr. Stombaugh's GLP GuideDr. Stombaugh's InstagramDr. Stombaugh's Tiktok Dr. Stombaugh's FacebookConquer Your Weight Podcast - AppleConquer Your Weight Podcast - SpotifyWays to Connect with Me:InstagramLinkedInWebsiteYouTube...Are you a professional woman over age 50 who's ready to lose weight for the last time? Join the Vibrant-MD weight loss course.Not sure if the Vibrant-MD weight loss course is right for you? Schedule a time to talk with Dr. Heather Awad directly to learn more.Sign up for our FREE course to get the step-by-step roadmap to permanent weight loss. You'll get a new formula that truly works for professional women over age 50, because it's long overdue that we say GOODBYE to the lousy old counting games.

On June 4, 2021, the FDA approved Wegovy for the treatment of chronic obesity and overweight individuals. Dr. John Sharretts, deputy director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA's Center for Drug Evaluation and Research, said, "Today's approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program. FDA remains committed to facilitating the development and approval of additional safe and effective therapies for adults with obesity or overweight." Read the full post at http://RunningAFEVER.com/413 Photo by Pavel Danilyuk: https://www.pexels.com/photo/woman-in-white-mesh-crop-top-and-pink-bra-7653700/

GLP-1 medications like Ozempic (semaglutide), Wegovy, and Mounjaro (tirzepatide) have transformed treatment for type 2 diabetes and weight loss — but they can also cause digestive side effects like nausea, diarrhea, constipation, bloating, and stomach pain that leave many patients confused or worried. In this episode, we're joined by Dr. Catherine Hudson from LSU Health New Orleans to separate fact from fiction and provide clear, evidence-based guidance. Dr. Hudson breaks down: How GLP-1 receptor agonists work Common digestive side effects—and how to manage them Why lifestyle changes still matter What you need to know before surgery or GI procedures when taking these medications Whether you're a patient, caregiver, or healthcare provider, this episode offers practical insights to help you navigate the GLP-1 journey with confidence. This episode is presented in collaboration with the American College of Gastroenterology's Patient Care Committee.  

On this week's episode, Chris Garabedian, Daphne Zohar, Sam Fazeli, Tess Cameron, Paul Matteis and Tim Opler share cautious optimism about the biotech market as IPOs and follow-ons gain momentum. Continuing on market sentiment, competitive pressure looms for small and mid-sized U.S. biotechs as the Chinese biotech market grows and big pharma continues to invest in these assets. Next, the group recapped #BIO2025, where sentiment was mixed due to sector uncertainty. In regulatory news, Daphne reflects on her time with Makary and Prasad at the FDA's listening tour, highlighting positive opportunities for biotech as the new administration takes shape. However, a report linking Makary to KalVista's rejection request stirred concerns. At ADA 2025, Lilly dominated the with positive results across its weight loss portfolio; Novo's data was also discussed. The group then covered Novo's cancellation of its partnership with HIMS due to concerns about the compounded versionof Wegovy. The conversation shifts to data, with Cidara's positive flu vaccine results, Compass' psilocybin data and Nektar's atopic dermatitis win. Additionally, Sarepta's Elevidys faces further safety questions and Capricor'scancelled AdCom raises worries of the FDA's flexibility.  The first ACIP meeting was also mentioned. On deals, Revolution Medicines' $2B deal with Royalty Pharma, Illumina's acquisition of SomaLogic and BlueRock's shutdown were overviewed. The episode concluded with a summary of the Royalty Pharma conference. *This episode aired on June 27, 2025.

Over 40 Muscle Building & Fat Loss Shortcuts with Stan Efferding The impact of ‘island time' on his overall health. (3:16) Shakes are for fakes, eat steaks! (11:55) Supplementation vs whole foods. (16:22) Busting cholesterol myths. (18:18) Energy intake versus energy expenditure with weight loss. (19:48) The components of lifting responsibly as you age. (25:14) Doing the least amount as possible to elicit the most amount of change. (39:08) The benefits of isometrics. (44:21) Eliminating junk volume. (53:19) The value trigger sessions. (58:03) His attitude toward sodium. (1:00:30) Peptide intervention: The good, the bad, and the ugly. (1:12:54) Related Links/Products Mentioned Visit Seed for an exclusive offer for Mind Pump listeners! **Promo code 25MINDPUMP at checkout for 25% off your first month's supply of Seed's DS-01® Daily Synbiotic** July Special: MAPS Split or Anabolic Metabolism Bundle 50% off! ** Code JULY50 at checkout ** Vertical Diet | By Stan Efferding Whole Egg Vs. Egg White Ingestion During 12 weeks of Resistance Training in Trained Young Males: A Randomized Controlled Trial Comparison of once‐weekly and twice‐weekly strength training in older adults Get your free Sample Pack with any “drink mix” purchase! Find your favorite LMNT flavor, or share it with a friend. Try LMNT totally risk-free. If you don't like it, give it away to a salty friend and we'll give you your money back, no questions asked! Visit DrinkLMNT.com/MindPump Stan Efferding - YouTube LEVELEN™ | The Leader in Athlete Sweat Testing | Sweat Test Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned Stan “Rhino” Efferding (@stanefferding) Instagram Website Mark Bell (@marksmellybell) Instagram Jay Cutler (@jaycutler) Instagram  Ronnie Coleman (@ronniecoleman8) Instagram Parrillo Performance (@parrilloperformance) Instagram Robb Wolf (@dasrobbwolf) Instagram Ben Carpenter (@bdccarpenter) Instagram Michael Israetel (@drmikeisraetel) Instagram Dr. William Seeds (@williamseedsmd) Instagram  

In this insightful episode, Molly sits down once again with Dr. Brooke Scheller, clinical nutritionist and founder of Functional Sobriety, to discuss one of the most buzzed-about topics in the health and wellness space: GLP-1 medications (like Ozempic and Wegovy). Originally developed for treating Type 2 diabetes and now widely prescribed for weight loss, these drugs are increasingly being talked about for their potential to reduce alcohol cravings.Together, Molly and Dr. Scheller unpack the growing curiosity (and concern) surrounding the off-label use of GLP-1s by those trying to moderate or change their drinking habits. They dive deep into both the science and the speculation—discussing small but intriguing studies, anecdotal feedback from clients and community members, and what it really means to find a “magic pill” for reducing desire.But this episode doesn't stop at surface-level discussion. They explore the bigger picture: sustainable behavior change, the role of nutrition in alcohol use, and whether it's possible to replicate the effects of GLP-1s with food, lifestyle, and mindset shifts alone.What You'll Learn in This Episode:What GLP-1 medications are and how they workWhy they might reduce alcohol cravings—and what the science says so farWho might benefit most from GLP-1s—and who should be cautiousCommon side effects and risks associated with these drugsNatural strategies to support craving reduction and metabolic healthWhy addressing core beliefs about alcohol is critical to long-term changeLinks & Resources Mentioned:Dr. Brooke Scheller's program: Functional SobrietyDr. Scheller's book: How to Eat to Change How You DrinkConnect with Molly: Website: www.mollywatts.com Instagram: @alcoholminimalist Join the Private Facebook Community: “Alcohol Minimalists: Change Your Drinking Habits”Want to Change Your Drinking? Download Molly's free guide “Alcohol Truths 2023” and learn how to identify your personal safe level of drinking at mollywatts.com/resourcesLow risk drinking guidelines from the NIAAA:Healthy men under 65:No more than 4 drinks in one day and no more than 14 drinks per week.Healthy women (all ages) and healthy men 65 and older:No more than 3 drinks in one day and no more than 7 drinks per week.One drink is defined as 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of 80-proof liquor. So remember that a mixed drink or full glass of wine are probably more than one drink.Abstinence from alcoholAbstinence from alcohol is the best choice for people who take medication(s) that interact with alcohol, have health conditions that could be exacerbated by alcohol (e.g. liver disease), are pregnant or may become pregnant or have had a problem with alcohol or another substance in the past.Benefits of “low-risk” drinkingFollowing these guidelines reduces the risk of health problems such as cancer, liver disease, reduced immunity, ulcers, sleep problems, complications of existing conditions, and more. It also reduces the risk of depression, social problems, and difficulties at school or work. ★ Support this podcast ★

In this Mini Mikkipedia Monday, I break down what you actually need to know about Wegovy (semaglutide), now available in New Zealand. There's a lot of noise around this weight loss medication—from the science to the stigma—and in this episode, I aim to cut through it with facts and context. I cover how GLP-1 agonists work, what makes them effective, and why they're not just another “quick fix.” From appetite suppression and craving control to weight maintenance and muscle loss concerns, I offer a balanced look at the pros, cons, and common misconceptions. Plus, I share my take on why we need less judgment and more empathy when it comes to using tools like these in our broken food environment.Highlights:The difference between Wegovy and Ozempic: use case and dosingHow GLP-1 receptor agonists impact appetite, cravings, and metabolic healthThe role of semaglutide in long-term weight loss and potential downsidesWhy muscle loss isn't a direct effect of the drug—and how to prevent itThe wider implications for public health and why lifestyle vs. medication is a false dichotomy Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwillidenSave 20% on all Nuzest Products WORLDWIDE with the code MIKKI at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comCurranz supplement: MIKKI saves you 25% at www.curranz.co.nz or www.curranz.co.uk off your first order

Karen tackles the surprising link between GLP-1 medication (like Ozempic and Wegovy) and hair loss. As more people turn to these drugs for diabetes and weight management, some are left wondering: is the price of shedding pounds also shedding your hair? Karen explores possible causes behind this side effect, including rapid weight loss, nutritional deficiencies, and hormonal changes, and shares science-backed strategies to help prevent or reduce hair thinning while on these medications.Visit our website itchyandbitchy.com to read blog posts on the many topics we have covered on the show.

Teenagers in the United States are using Wegovy and other weight-loss drugs at quickly rising rates. On this special episode of Reuters World News, we look at the decisions facing parents and children in the battle against childhood obesity. Sign up for the Reuters Econ World newsletter here. Listen to the Reuters Econ World podcast here. Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices.You may also visit megaphone.fm/adchoices to opt out of targeted advertising. Learn more about your ad choices. Visit megaphone.fm/adchoices

Kathryn welcomes back Marcus Kain for a thoughtful conversation about the increasing use of GLP-1 medications (like Ozempic and Wegovy) in the context of binge eating recovery and weight loss. They discuss the significant risks—especially for those with a history of restrictive eating—while also acknowledging that some individuals have experienced benefits when these medications are used cautiously under medical supervision. This episode is not to provide medical advice or promote the use of any medication; it's an honest, nuanced discussion about a complex and evolving topic. Kathryn and Marcus hold space for differing perspectives and emphasize that full recovery is absolutely possible and unique to each individual. Episodes mentioned on this show: Ep. 131: Ozempic and Eating Disorders with Robyn Goldberg RDN, CEDS-C Ep. 90: Letting Go of Unrealistic Recovery Goals and Unhealthy Fitness Standards (with Marcus Kain) Ep. 119: How Does Fitness Fit Into Recovery? (with Marcus Kain) Ep. 167: Healthy Goal Setting and Sustainable Change in the New Year (with Marcus Kain) Learn more about Marcus Kain: StrongNotStarving.com Instagram: @strongnotstarving Strong Not Starving podcast Brain over Binge resources: Get the FREE 30-day Inspiration Booklet Get personalized support with one-on-one coaching or group coaching Subscribe to the Brain over Binge Course for only $18.99 per month Get the Second Edition of Brain over Binge on Amazon and Audible, BarnesandNoble.com, Apple iBooks, or Kobo. Get the Brain over Binge Recovery Guide   Disclaimer: *The Brain over Binge Podcast is produced and recorded by Brain over Binge Recovery Coaching, LLC. All work is copyrighted by Brain over Binge Recovery Coaching, LLC, and all rights are reserved. As a disclaimer, the hosts of the Brain over Binge Podcast are not professional counselors or licensed healthcare providers, and this podcast is not a substitute for medical advice or any form of professional therapy. Eating disorders can have serious health consequences and you are strongly advised to seek medical attention for matters relating to your health. Please get help when you need it, and good luck on your journey.

Weight loss injections are a huge story in the diet world right now. This is a special episode of the podcast, where we hear from people who have experience of using the Mounjaro and Wegovy jabs. You'll get stories from people have had good, bad and every other kind of experience with injections. Some of our contributors have got their jabs via the NHS, others have sourced them privately. We have information about the costs involved, should you want to do the same. Plus we hear from people who have chosen not to try the jabs and why. Send us a voicenote: 07468 286104 If you'd like to mark your weight loss with our exclusive certificates, get Extra Portions of this podcast and win CASH PRIZES go to patreon.com/noshameinagain or find us on the Patreon app. Hosted on Acast. See acast.com/privacy for more information.

Sarah Kennedy of Calocurb discusses the natural and medical ways to suppress appetite, focusing on the revolutionary GLP-1 agonists (like Ozempic and Wegovy). This is truly a deep dive into the mechanism of GLP-1 and its role in regulating appetite and blood sugar. You will learn all about the innovative Calocurb supplement, founded by Sarah, which uses a patented hops extract to effectively increase GLP-1 and reduce calorie intake by 18%. A must-watch for women in midlife looking to manage their weight naturally.Go to https://calocurb.com/drstephanie to get 10% off your first purchaseEpisode overview (timestamps are approximate):(0:00) Intro/Teaser(7:00) Understanding GLP-1 and Appetite Suppression(24:00) Exploring the Effects of CaloCurb(39:00) Mechanism and Benefits of CaloCurb(43:00) Practical Strategies for Managing Hunger and Stress Eating(54:00) Research and the Future of Natural Appetite Suppression(1:03:00) BONUS: Dr. Stephanie's "After Party"Resources mentioned in this episode can be found at https://drstephanieestima.com/podcasts/ep425A huge thanks to our sponsors:BEAM MINERALS - Replenish essential minerals your body needs. Visit https://beamminerals.com/better for 20% off of the entire store. The discount is auto-applied at checkout.LVLUP  - Midlife hormonal changes can wreak havoc on your gut health. Ultimate GI Repair combines powerful gut-healing peptides with gut-nourishing naturals to soothe your changing digestion. Learn more at https://lvluphealth.com/DRSTEPHANIE and use code DRSTEPHANIE for 15% off.TIMELINE - As perimenopausal women, we know we are in a fight against time to preserve our muscle strength and endurance, plus our recovery needs are greater. That's why you save 20% at https://timelinenutrition.com/better with code BETTER.MAUI NUI VENISON - Packed with essential vitamins, minerals, and bioavailable compounds that support energy, performance, and overall health. Head over to  https://mauinuivenison.com/better to checkout their premium snack sticks and fresh starter boxes.

Welcome to my Summer Throwback Playlist—a handpicked collection of the most downloaded episodes of the podcast. These are listener favorites, packed with insights, laughs, and empowered eating encouragement to keep you fueled all summer long. A quick heads up: since these are throwbacks, you might hear old references to programs or events that are no longer active—but the heart of each episode still hits. Let's dive in and revisit the best of the best! In this episode, we're diving into one of the most talked-about weight loss medications on the market: Ozempic—also known by names like Wegovy and Mounjaro. You've likely seen the buzz: celebrity endorsements, dramatic TikTok before-and-afters, and headlines calling it a “miracle drug.” I've had clients take it, ask about it, swear by it, and question it. I've also heard from colleagues with very strong opinions on both sides. So, what's the truth? What is Ozempic really designed for? How does it work? Does it actually help with weight loss? And most importantly—is it safe? I'm sharing a brief overview of the science, my clinical observations, and why this conversation matters—especially in a world where body image, quick fixes, and long-term health often clash. ⚠️ Trigger Warning: If you're currently struggling with or recovering from an eating disorder, please listen with care or consider skipping this episode. Ozempic is contraindicated for anyone with a history of eating disorders. Want to go deeper? I reference two excellent episodes that continue this conversation: "Science Vs." and "Honestly".

What if We're Using GLP-1 Medications All Wrong?Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we're not harnessing their full therapeutic potential?In this eye-opening conversation, Dr. Ben Bikman, metabolic health researcher and professor at BYU, joins Dr. Bret Scher to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health.Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach:Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbsUsing the medication as a temporary metabolic tool to support transitions to lower-carb dietsReducing long-term risks such as muscle loss, mood changes, and diminishing effectivenessEmphasizing the importance of habit change, insulin regulation, and muscle preservationThis conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies.

GLP-1 medications like Ozempic and Wegovy are everywhere right now. But what are they really? And should you use them for weight loss? In this episode, I'm breaking down exactly what GLP-1 agonist medications do, how they work in your body, and the big-picture pros and cons—especially if you're a busy mom trying to lose weight in a sustainable way. I also share my perspective as someone who used to work in a bariatric clinic and has seen what happens when people rely on weight loss tools without building the habits to support them. What you'll learn: What GLP-1 medications are and how they promote weight loss The real concern with muscle loss on these meds Why strength training and protein matter more than ever How to protect your metabolism during weight loss What it actually takes to maintain results long term If you're taking a GLP-1, thinking about it, or just trying to lose weight and feel good in your body, this episode will help you understand how to build a plan that works with or without medication. Because fat loss might be the goal—but muscle and metabolism are what keep it off.

Did you know that stopping GLP-1 medications like Ozempic or Wegovy can trigger powerful biological and emotional changes that impact your weight journey? In this episode, I talk about what happens when you stop taking a GLP-1 medication, like Ozempic, Wegovy, or Zepbound. I explain how these medications work by slowing stomach emptying, reducing appetite, and helping with insulin regulation, which supports weight loss and benefits conditions like type 2 diabetes and PCOS. However, I also share that they're not magic pills, you still need healthy habits like eating well and exercising. I highlight possible side effects, such as nausea or pancreatitis risks, and emphasize that stopping these medications can lead to increased hunger, cravings, weight regain, and even emotional distress. But I also reassure you that this isn't a sign of failure. Weight regain is often biological, not personal. I offer tips for tapering off safely, reinforcing lifestyle habits, and exploring other options. Most importantly, I remind you that your journey is valid, you're not alone, and lasting success requires a plan, support, and self-compassion. Tune in to learn what really happens when you stop taking GLP-1 medications—and how to stay empowered and in control of your weight journey.   Episode Highlights: How GLP-1 medications like Ozempic and Wegovy work Common side effects and safety considerations What to expect when stopping GLP-1s, both physically and emotionally Strategies to manage weight regain and maintain healthy habits Alternative tools and support options beyond medication Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In this episode of Hey, Coach Radio, host William Grazione discusses the increasing use of GLP-1 peptides like Wegovy and Ozempic in the fitness industry and their potential side effects, including lean body mass loss, bone loss, and gastrointestinal issues.  William provides unconventional tips to mitigate these effects, such as detoxifying the body, maintaining a high-protein diet, engaging in resistance training, optimizing sleep, and resetting cortisol levels. These strategies aim to help users maintain muscle and bone mass, improve metabolic health, and enhance overall well-being.  

Alice looks at the science underpinning Ozempic and Wegovy, and the impact they have on society. Meanwhile, Mike goes to see Hamilton again. And again. And again.Online tickets for the final QED are still available, pick up yours today. You can also chat with us on the Skeptics in the Pub Discord server.You can sign up for the Skeptics with a K Patreon at https://patreon.com/skepticswithak, or to support Merseyside Skeptics as well as the podcast, donate at https://patreon.com/merseyskepticsMixed and edited by Morgan Clarke.

GLP-1 medications like Ozempic have dominated headlines over the past couple of years. When writing his new book, Diet, Drugs and Dopamine: The New Science of Achieving a Healthy Weight, former FDA commissioner David Kessler wanted to unpack the science beyond those headlines. He also has a personal relationship with the subject, having taken GLP-1 medications himself. Host Flora Lichtman joins Kessler to talk about the latest science on metabolism, weight loss, and how these blockbuster drugs actually work.Guest: Dr. David Kessler is the former commissioner of the FDA and the author of Diet, Drugs and Dopamine: The New Science of Achieving a Healthy Weight.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

This week, we're diving into the stories shaping what we eat, how we shop and the way we live. We're talking about the government's new push to tackle obesity by cutting just 50 calories a day, whether weight-loss jabs like Wegovy and Mounjaro are already changing our shopping habits, and the latest on possible bans or tighter rules for alcohol advertising in the UK. We also get into which oils you actually want to be cooking with at home, why M&S has just trademarked something called “Punishment Juice,” and a major new NHS survey that reveals one in four young adults are now living with a mental health condition. Plus, could creatine help prevent Alzheimer's? We look at what the science says so far — along with all our personal updates and this week's recommendations, from cult podcasts to berry-packed smoothies. This week's recs: Korean exfoliating mitt⁠ ⁠How I Became a Brainwashed Cult Bride⁠ on Conversations (ABC Australia) Get your copy of Rhi's new book 'The Unprocessed Plate' ⁠⁠HERE⁠ Vote for us to win the Listener's Choice award at the British Podcast Awards: https://www.britishpodcastawards.com/voting Learn more about your ad choices. Visit podcastchoices.com/adchoices

I am honored to reconnect with Dr. Tracy Gapin today. He is a board-certified urologist and men's health expert.  The current state of metabolic health in the United States and most Westernized countries has sparked a great interest in a GLP1 agonist, AKA Semaglutide Ozempic. I wanted to speak with a clinician who actively uses this medication. Dr. Gapin and I discuss what this drug class represents. (These are synthetic peptides.) We speak about Semaglutide, Ozempic, Wegovy, and oral Rybelsus. We get into current research, side effects, who should not take these medications, the mechanisms of action specific to the pancreas and beta cells, reductions, gastric emptying, and the upregulation of satiety. We discuss changes in the brain regarding leptin and how these drugs work. We also talk about weight loss resistance, and I answer questions from listeners.  From my perspective, it all comes back to basics. I believe that if we are to prescribe these medications, we must help our patients understand how lifestyle impacts weight-loss resistance and metabolic health. I loved that Dr. Tracy spent some time talking about the specific ways he works with his patients, even before prescribing medications. He also explains how important he feels this drug has been for his patients. I approached today's conversation with an open mind, and I hope you will do the same. IN THIS EPISODE YOU WILL LEARN: GLP1 agonists, and how they help Dr. Tracy motivate his patients to lose weight What are GLP1 agonists, and how do they work? Physical benefits of GLP1 agonists Who is Semaglutide not appropriate for? Common side-effects of GLP1 agonists How those who fail to implement lifestyle changes when they stop using Semaglutide may regain all the weight they lost Hydration while using Semaglutide Protein intake when taking Semaglutide How to follow the metrics that matter Factors that could hinder successful weight loss What Dr. Tracy does to ensure his patients do not regain the weight they lost after they stop using Semaglutide Listener questions: Why is a diabetic drug being used for non-diabetics? Does this drug target muscle versus fat in terms of weight loss? For how long do most patients take it? Are there unique characteristics in perimenopausal and menopausal women that must be accounted for differently? Bio: Dr. Tracy Gapin is a board-certified urologist and a world-renowned expert in men's health and performance, as well as the founder of the Gapin Institute, the global leader in High-Performance Health.  He has over 20 years of experience focused on men's health optimization, human performance, and longevity, providing executives & entrepreneurs a personalized path to fulfill their highest potential. He's been featured in Entrepreneur, Dave Asprey's Biohacking Conference, and as a TEDx speaker. Connect with Cynthia Thurlow Follow on⁠ Twitter⁠,⁠ Instagram⁠ &⁠ LinkedIn⁠ Check out Cynthia's⁠ website⁠ Connect with Tracy Gapin On his⁠ website⁠ ⁠Gapin Institute⁠

Fat Loss & Metabolism with Dr. Ben Bikman Challenging the dogma surrounding heart disease. (1:32) Is there a connection between dementia and heart disease? (12:05) Strength training and Alzheimer's. (17:49) Learning something new helps put off dementia. (22:45) The connection between insulin resistance and your body's inability to fight off infection. (25:17) We put TOO much attention on total cholesterol. (27:55) Fat cells dynamics explained. (30:13) Why your metabolism is EXTREMELY complex. (44:14) Mitochondrial uncoupling. (48:51) Ketones and athletic performance. (55:39) The problem with DNP. (58:11) Why he is a HUGE advocate of creatine. (1:01:03) The brain loves ketones. (1:04:33) Keep your running shoes in the closet, GO STRENGTH TRAIN! (1:05:32) The metabolic origins of chronic disease. (1:08:10) How GLP-1s are being overused and the proper way to use them. (1:14:48) The resurgence of religion. (1:37:57) As a scientist, did he ever doubt his faith? (1:41:28) The most profound moment of his life. (1:45:51) Related Links/Products Mentioned Why We Get Sick: The Hidden Epidemic at the Root of Most Chronic Disease - and How to Fight It – Book by Dr. Benjamin Bikman How Not to Get Sick: A Cookbook and Guide to Prevent and Reverse Insulin Resistance, Lose Weight, and Fight Chronic Disease – Book by Dr. Benjamin Bikman Unlock sharper focus and support long-term brain health with Ketone-IQ—clean brain fuel for deep work, mental clarity, and sustained energy with no crash. Get 30% off your subscription, plus a free gift with your second shipment at https://ketone.com/MINDPUMP June Special: Shredded Summer Bundle or Bikini Bundle 50% off! ** Code JUNE50 at checkout ** Most heart attack patients' cholesterol levels did not indicate cardiac risk Study: Doubling Saturated Fat in the Diet Does Not Increase Saturated Fat in Blood Insulin signal transduction pathway Mind Pump #1922: Fatphobia & Other Lies That Are Keeping You Fat, Unhealthy & Sick Diabulimia: Why This Eating Disorder Is So Dangerous for People with Diabetes Harris-Benedict equation - Wikipedia Mitochondrial Uncoupling: A Key Controller of Biological Processes in Physiology and Diseases DNP (Dinitrophenol): Overview, Mechanism, and Risks Mind Pump #2497: The Amazing & Weird Side Effects of Creatine Muscle strength and fitness linked to reduction in cancer deaths Fighting Cancer By Putting Tumor Cells On A Diet - NPR Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined Attenuated GLP-1 secretion in obesity: cause or consequence? Mind Pump #2597: Before You Take Ozempic, Wegovy, or Mounjaro Listen to This! Liraglutide modulates lipid metabolism via ZBTB20-LPL pathway Mind Pump #872: Dr. Warren Farrell- The Boy Crisis Mind Pump Podcast – YouTube Mind Pump Free Resources Featured Guest/People Mentioned Benjamin Bikman (@benbikmanphd) Instagram Website Zach Bitter (@zachbitter) Instagram  Thomas N. Seyfried (@thomasseyfriedbc) Instagram Warren Farrell, PhD (@drwarrenfarrell) X/Twitter